amikacin sulfate / Generic mfg. - LARVOL DELTA

Phages targeting highly prevalent Greek multidrug-resistant Pseudomonas aeruginosa clinical isolates: In vitro and in vivo data. (PubMed, Virology) - "The in vivo pharmacokinetics and therapeutic efficacy of intranasally administered phages, given alone or in combination with intraperitoneally administered amikacin, were evaluated in a murine lung infection model using a clinical MBL-PA isolate...Strong lytic activity and a relatively broad spectrum within the tested isolate collection were observed among the isolated phages against MBL-producing P. aeruginosa isolates. Selected phages exhibited high lytic activity even at the lowest multiplicity of infection tested, making them promising candidates for further investigation in efforts to control multidrug-resistant P. aeruginosa infections, particularly when combined with antibiotics."

Journal • Preclinical • Infectious Disease • Respiratory Diseases

Postoperative outcomes following institutional antibiotic protocol changes in complicated pediatric appendicitis. (PubMed, World J Pediatr Surg) - "Pediatric patients with complicated appendicitis were compared across two sequential first-line empirical antibiotic protocol periods: amikacin plus metronidazole (period 1) changed to ampicillin-sulbactam (period 2). Disease severity, particularly generalized peritonitis, was the main factor associated with intra-abdominal abscess formation. These findings support prioritizing early severity assessment and source control over modifications in empirical antibiotic selection."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pediatrics

Immediate Laparoscopic Appendectomy Versus Interval Laparoscopic Appendectomy for Early Appendicular Mass (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: Assiut University

New trial • Gastroenterology • Gastrointestinal Disorder

Elucidating the mechanism of amikacin-induced acute kidney injury: a multilevel analysis based on the FAERS database and network toxicology. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "GEO analysis corroborated the predicted upregulation of IL1B and CXCL8 in AKI, and further supported the involvement of PTGS2, which was significantly upregulated in a cisplatin‑induced AKI model. This study delineates the risk profile of amikacin-associated AKI and elucidates a molecular mechanism involving multi-target interactions in renal injury induction, thereby offering a theoretical basis and identifying potential molecular targets for further investigation into clinical risk mitigation strategies."

Journal • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease • CXCL8 • IL1B • PACERR • PTGS2 • SIRT1

Combatting a Tobramycin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit: the impact of hygiene intervention and antibiotic substitution. (PubMed, BMC Infect Dis) - "Our findings underscore the interplay between the ward environment and neonatal colonization, emphasizing that successful outbreak control requires a combination of adherence to hygiene routines, pasteurization of DHM, and a correct antibiotic regimen."

Journal • Retrospective data • Critical care • Infectious Disease

Comparison of Antibiotic Prophylaxis Regimens for Preventing Prostatitis After Transrectal Ultrasound-Guided Prostate Biopsy. (PubMed, Cureus) - "A single dose of IM ertapenem or amikacin appears to be associated with a lower risk of infections after a TRUS-guided prostate biopsy. They may represent a potential prophylactic alternative to fluoroquinolone-based regimens, especially in places where routine rectal culture-guided prophylaxis is not done."

Journal • Genito-urinary Cancer • Infectious Disease • Oncology • Prostate Cancer • Septic Shock • Solid Tumor

Association between dexmedetomidine use and acute kidney injury in critically ill patients treated with amikacin. (PubMed, Drug Chem Toxicol) - "Dexmedetomidine use was associated with lower odds of AKI in critically ill patients receiving amikacin. Prospective studies are warranted to confirm these findings."

Journal • Acute Kidney Injury • Anesthesia • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Infectious Disease • Nephrology • Renal Disease

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: University Hospital, Ghent | Trial completion date: Jul 2026 ➔ Jul 2029 | Trial primary completion date: Jul 2026 ➔ Jul 2029

Trial completion date • Trial primary completion date • Pediatrics

Double zoonosis: Parinaud oculoglandular syndrome from sporotrichosis and follicular conjunctivitis from Moraxella osloensis, a zoonotic co-infection from our feline friend. (PubMed, Med Mycol Case Rep) - "Oral itraconazole, topical amphotericin B and amikacin achieved remission. Although Bartonella henselae is the commonest cause of POGS, Sporothrix schenckii warrants consideration in cat-exposed patients, alongside bacterial co-infection."

Journal • Conjunctivitis • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Prevalence and Antibiotic Resistance Pattern of Escherichia coli Isolated from Urine Samples of Pediatric Outpatients with Underlying Medical Conditions from Pakistan. (PubMed, Infect Drug Resist) - "The highest rates of resistance were observed against ampicillin (70.3%), cephalexin (60.1%), and trimethoprim-sulfamethoxazole (59.4%). Low resistance was noted to nitrofurantoin (2.8%) and amikacin (1.8%). Age was a significant predictor, with 1-year old children showing 2.1-fold 95% CI: 1.01-4.55) and 3.6‑fold (95% CI: 1.60-8.15) increased odds of ESBL production and MDR, respectively, compared to children aged 6-12 years. High rates of ESBL-producing and MDR E. coli in Pakistani children with underlying conditions underscore the critical need for antimicrobial stewardship and empirical therapy guided by local susceptibility patterns, particularly in younger children."

Journal • Infectious Disease • Nephrology • Pediatrics

Molecular epidemiology of antimicrobial-resistant Klebsiella pneumoniae in intensive care unit patients, southwestern Saudi Arabia. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "The highest resistance rates were observed against piperacillin‑tazobactam (55.1%), cefotaxime (55.1%), imipenem (53.0%), and meropenem (53.0%), while tigecycline (100% susceptibility) and amikacin (93.9% susceptibility) remained the most effective agents. Notably, susceptibility to trimethoprim‑sulfamethoxazole was 83.7% (corrected figure)...The alarmingly high prevalence of ESBL and carbapenemase phenotypes, coupled with significant multidrug resistance, underscores the urgent need for routine molecular surveillance and targeted antibiotic stewardship in this region. Rapid phenotypic screening combined with genotypic confirmation is essential to guide empirical therapy and curb the spread of these high‑risk clones in critically ill populations."

Journal • Retrospective data • Critical care • Infectious Disease • Pneumonia

Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: a multicentre study. (PubMed, Int J Antimicrob Agents) - "Bronchiectasis-associated P. aeruginosa constitutes a polyclonal, genetically heterogeneous population. Non-susceptibility predominantly reflects intrinsic and adaptive genomic mechanisms. Given the high fluoroquinolone resistance observed, treatment should be guided by local resistance patterns and isolate-specific susceptibility results."

Journal • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Cohort profile: Infant Gut Bacterial Study in Pakistan (INBUGS-P) longitudinal birth cohort. (PubMed, BMJ Open) - "Antibiotics were prescribed to almost all mothers following delivery, and 19 infants received antibiotics during follow-up, most commonly amikacin combined with ceftazidime. Shotgun metagenomic sequencing of infant stool samples is underway to enable species-level and plasmid-level profiling of microbial communities and ARGs. Subject to funding, hybrid long- and short-read sequencing and extended follow-up to 24 months are planned."

Journal

Late Breaking Abstract - Microbiologic outcomes and recurrence in patients with newly diagnosed Mycobacterium avium complex lung disease (MACLD) in the phase 3b ENCORE trial (ERS 2026) - P3 | "Aims and Objectives: We present data from ENCORE (NCT04677569), a phase 3b, randomized, placebo-controlled, multinational, active comparator, superiority trial, which evaluated efficacy and safety of 12 months of amikacin liposome inhalation suspension (ALIS) with MDT in adults newly diagnosed with MACLD who have not initiated antibiotics... Eligible patients were randomized 1:1 to receive once daily MDT (azithromycin 250 mg and ethambutol 15 mg/kg) with either ALIS 590 mg or comparator (empty liposome control) for 12 months... The ENCORE study demonstrated superior respiratory symptom improvement and microbiological efficacy, along with lower recurrence rates in the ALIS arm versus comparator arm in patients with newly diagnosed MACLD who have not initiated antibiotics."

Clinical • Late-breaking abstract • P3 data • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Effect of Prophylactic Inhaled Amikacin on Ventilator-Associated Pneumonia and Clinical Outcomes in Mechanically Ventilated Children: A Randomised Controlled Trial (ERS 2026) - "Prophylactic inhaled amikacin did not reduce the proportion of children developing VAP, delay disease onset, or improve secondary clinical outcomes, indicating limited preventive benefit in the PICU."

Clinical • Clinical data • Acute Kidney Injury • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases

Virtual reality hearing tests to monitor aminoglycoside-induced ototoxicity in respiratory patients (ERS 2026) - "Results Between 13/3/22-15/9/23, 8 patients completed the study: mean age 41±13 years; 3 were female; 2 received amikacin (non-tuberculosis mycobacteria infection); 6 received tobramycin (3 cystic fibrosis (CF), 3 non-CF bronchiectasis)...Conclusion The pilot study suggests TA is accurate compared with the gold standard (SBA), showing acceptable correlation between SSIN-VA test scores and TA. However, further work is required to optimise usability and digital technology literacy in a chronic respiratory infection cohort."

Clinical • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Role of nebulised amikacin as an 'adjunct' to standard care in recurrent exacerbation Bronchiectasis during acute care hospitalization and follow-up period of 52 weeks (ERS 2026) - "Nebulized amikacin significantly reduced hospitalization, exacerbation frequency, severity, and duration, while increasing exacerbation-free days & cost effective option in drug-resistant bronchiectasis in resourse limited settings."

Clinical • Bronchiectasis • Nephrology • Pulmonary Disease • Respiratory Diseases

Comparative effectiveness of standard regimen with vs without intravenous amikacin in cavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease (ERS 2026) - "Conclusions In patients with cavitary NB type MAC-PD, overall outcomes appeared broadly similar between standard regimen alone and standard regimen with AMK-IV. Adjunctive AMK-IV may be associated with earlier sputum culture conversion, although confirmation in larger studies is warranted."

HEOR • Pulmonary Disease • Respiratory Diseases

Omadacycline as an alternative to macrolides within maintenance regime for Mycobacterium abscessus pulmonary disease in children with Cystic Fibrosis: Adapting pharmacotherapy in response to emerging macrolide resistance (ERS 2026) - "BACKGROUND: Mycobacterium abscessus infection in children with cystic fibrosis (CF) presents major therapeutic challenges, including inducible(erm gene) resistance to macrolide antibiotics (e.g. Azithromycin) which have bacteriostatic action and may negatively impact the bactericidal action of aminoglycosides when used in combination. Omadacycline, a novel tetracycline antibiotic with activity against non-tuberculous mycobacteria (NTM), offers an effective alternative to macrolides...Following an intensification regime of 3 weeks of intravenous cefoxitin, meropenem and amikacin, omadacycline was incorporated into maintenance therapy alongside clofazimine and nebulised amikacin... Emerging evidence of inducible resistance in M.abscessus isolates may impact success of eradication when using macrolides. Omadacycline appears to be an effective alternative to macrolides in achieving successful culture conversion when used in maintenance therapy for NTM-PD."

Clinical • Chronic Cough • Cough • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Children: A Secondary Analysis of a Randomised Controlled Trial (ERS 2026) - " This secondary analysis utilised data from an open-label RCT evaluating prophylactic inhaled amikacin for VAP prevention, conducted in a tertiary-care PICU in India between April 2024 and October 2025... VAP was most commonly associated with delay in PICU transfer, prolonged ventilation, respiratory illness, and AKI."

Clinical • Acute Kidney Injury • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases

Potential efficacy of Streptomycin in AMK-resistant Mycobacterium avium-intracellulare complex pulmonary disease (ERS 2026) - "Background: In the treatment of refractory Mycobacterium avium-intracellulare complex pulmonary disease (MACPD), aminoglycoside drugs, amikacin (AMK), streptomycin (SM), and amikacin liposome inhalation suspension have important roles... SM may represent a potential treatment option for selected patients with AMK-resistant MACPD. Furthermore, measurement of SM MICs with CAMHB appears to be justified."

Clinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clinical factors associated with culture conversion in refractory Mycobacterium avium complex-pulmonary disease treated with amikacin liposome inhalation suspension: a meta-analysis (ERS 2026) - "RATIONALE: Amikacin liposome inhalation suspension (ALIS) is an adjunctive therapy for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We found four papers and evaluated 135 patients (23 males, 112 females) who were given ALIS therapy for more than 4 months in this meta-analysis. Mycobacterium avium and Mycobacterium intracellulare were identified in 101 and 34 cases, respectively. Cavitary lesions and clarithromycin (CAM) resistance were present in 85 and 43 patients, respectively."

Retrospective data • CNS Disorders • Respiratory Diseases

Incidence and Timing of Adverse Events During Treatment for Pulmonary Mycobacterium avium complex Disease: A Prospective Cohort Study (ERS 2026) - "Initial regimens included a standard three-drug regimen (rifampicin, ethambutol, and a macrolide) in 89 patients, additional intravenous amikacin in 15, ethambutol plus azithromycin in 3, and other regimens in 4. Adverse events occurred in nearly 90% of patients during pulmonary MAC treatment, mostly in the early phase, but were generally low-grade. These results indicate that early proactive monitoring may allow continuation of standard therapy despite the high AE frequency."

Adverse events • Clinical • Anorexia • Hematological Disorders • Neutropenia • Thrombocytopenia

NTM-Pulmonary Disease, Response to Treatment and Survival; A Single Centre Cohort Study. (ERS 2026) - "26/84 treated with Ethambutol(E), Macrolide (M), Rifampicin (R), and 7/11 cases EMR plus Amikacin for cavitatory/severe disease. 84 patients age (med, range) 73 (19-90) yrs, 54.5% female. COPD 47% (F 31%, M 59%, P<0.01), Bronchiectasis 33% (F 54.2% M 10 % p< 0.001). CT scan: Bronchiectasis 23.3%, Nodular-Bronchiectatic 29%, Cavitating 16.3%, Other 31.4%,."

Clinical • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Diagnostic and management challenges in dual-pathogen culture-negative endocarditis: a case report of Brucella Canis native valve infective endocarditis and subsequent saccharomyces cerevisiae prosthetic valve infective endocarditis. (PubMed, Diagn Microbiol Infect Dis) - "This case highlights suspecting rough Brucella in culture-negative infective endocarditis, evaluating unexpected molecular fungal detections alongside histology, and tailoring regimens around severe antimicrobial toxicities."

Journal • Cardiovascular • Gastrointestinal Disorder • Infectious Disease